Health In Tech Reports Strong 71% Full-Year Revenue Growth, Projects 35-50% Growth for 2026
HIT has more than doubled off its 52-week low of $0.512.
Summary
Health In Tech reported full-year 2025 revenues of $33.3 million, up 71% year-over-year, and issued 2026 revenue guidance of $45 million to $50 million, representing 35-50% growth.
Key Events · Earnings and Guidance · HIT
-
Strong Full-Year 2025 Revenue Growth
Reported full-year 2025 revenues of $33.3 million, a 71% increase year-over-year.
-
Positive 2026 Revenue Guidance
Projected full-year 2026 revenue to be in the range of $45 million to $50 million, indicating 35% to 50% year-over-year growth.
-
Increased Full-Year Adjusted EBITDA
Achieved full-year 2025 Adjusted EBITDA of $4.1 million, up 81% year-over-year.
-
Mixed Q4 2025 Profitability
Reported a Q4 2025 Adjusted EBITDA of $0.3 million, down from $0.5 million in the prior year, and a net loss of $0.3 million compared to a $0.1 million net loss in Q4 2024.
Analysis · HIT · Finance
Health In Tech, Inc. announced robust full-year 2025 financial results, highlighted by a 71% increase in revenues and an 81% rise in Adjusted EBITDA. The company also provided strong revenue guidance for 2026, projecting 35% to 50% year-over-year growth. While Q4 2025 saw a decline in Adjusted EBITDA and a net loss compared to the prior year, the overall trajectory and forward outlook remain positive, driven by expanding distribution and new AI-enabled platform features. Investors should monitor the company's ability to translate top-line growth into consistent profitability in upcoming quarters.
At the time of this filing, HIT was trading at $1.73 on NASDAQ in the Finance sector, with a market capitalization of approximately $103M. The 52-week trading range was $0.51 to $4.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.